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The major task of the European Society of Clinical Microbi-
ology and Infectious Diseases (ESCMID) is to improve the
diagnosis, treatment and prevention of infection-related dis-
eases. This is achieved by promoting and supporting
research, education, training, and good medical practice.
Those concerned are informed in many ways of new ﬁndings
and of state-of-the-art prevention, diagnosis and treatment
of infections. At the 22nd European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID 2012), held
from 31 March to 3 April 2012 in London, UK, Clostridium
difﬁcile was the topic of a symposium titled ‘The epidemiol-
ogy and clinical relevance of Clostridium difﬁcile in speciﬁc
populations’ and of another symposium entitled ‘Breaking the
cycle of recurrent Clostridium difﬁcile infections’. The current
supplement to Clinical Microbiology and Infection, the ofﬁcial
ESCMID journal, now summarizes the proceedings of the lat-
ter symposium in order to further emphasize the importance
of C. difﬁcile infection (CDI) [1–5]. Joint efforts by all involved
in the healthcare system are necessary to minimize the
spread of C. difﬁcile in healthcare facilities and to increase the
quality of diagnosis and treatment of CDI. Highlighting the
importance of CDI is of the utmost importance internation-
ally and, as deﬁned by the WHO concept of ‘Patient Safety’,
in the best interests of patients. The supplement reviews the
expertise of present activities to combat CDI. It attests to
the fact that nosocomial diarrhoea is no longer a mere nui-
sance but a serious public health problem. Responding to this
pivotal challenge to patient safety requires many activities.
Elderly patients are more susceptible to CDI in general and
to infections with resistant pathogens in particular, because
of a higher likelihood of exposure to antibiotics than in
younger populations. The fact that the elderly are adversely
affected by CDI to a greater degree than the young could
explain why the public health relevance of this illness is still
under-appreciated in many countries. My home country,
Austria, is a ‘good’ example. The three cases of fatal CDI
reported by the Austrian Health Authorities for the year
2011 are in stark contrast to the ﬁndings of a recent Aus-
trian study, which concluded that ‘based on incidence rate
and case fatality observed in our study in one acute care
hospital, a total of 7097 cases of hospital-acquired CDI
resulting in an estimated 1279 deaths could be expected
every year in Austria’ [6,7]. Dedicating a supplement of CMI
to the topic of CDI reﬂects our desire to raise awareness
and to support education and good medical practice in the
ﬁght against this often underestimated illness.
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